英国首先批准治疗鼻喉癌和食道癌的Toripalimab。 UK approves toripalimab for treating nasopharyngeal and esophageal cancers, first of its kind.

联合王国卫生部已经批准Tripalimab,这是Junshi生物科学公司的一种抗PD-1的药物,用于治疗鼻喉癌和食道癌。 The UK MHRA has approved toripalimab, an anti-PD-1 drug by Junshi Biosciences, for treating nasopharyngeal and esophageal cancers. 它是英国治疗鼻咽癌的第一种药物，也是英国晚期食管鳞状细胞癌的唯一一线治疗药物，无论 PD-L1 状态如何。 It's the first drug for nasopharyngeal carcinoma and the only first-line treatment for advanced esophageal squamous cell carcinoma in the UK, regardless of PD-L1 status. 批准的依据是表明药物在与化疗相结合时的安全性和有效性的研究。 Approval is based on studies showing the drug's safety and efficacy when combined with chemotherapy.